Clinical trial
Sitagliptin Added-on to Insulin Study (0431-051)
NCT00395343 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00395343 |
|---|---|
| Title | Sitagliptin Added-on to Insulin Study (0431-051) |
| Official title | A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK0431) to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or In Combination With Metformin) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | sitagliptin phosphate, Comparator : placebo (unspecified) |
| Enrollment | 641 |
| Start date | Dec 11, 2006 |
| Primary completion | Oct 13, 2008 |
| Completion | Oct 13, 2008 |
| First posted | Nov 2, 2006 |
| Last update posted | May 12, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: